Can-Fite Biopharma reported longer-than-expected blinded overall survival in its Phase 3 Namodenoson trial for advanced hepatocellular carcinoma (Child-Pugh B7). While data remain blinded and efficacy is not yet proven, management is considering an earlier interim analysis. Separately, CANF announced a warrant exercise for up to 1,591,738 ADSs at $2.50, generating about $4 million gross to fund R&D and clinical activities.
Can-Fite Biopharma reported positive updated safety and survival data for Namodenoson in a 20-patient open-label trial, prompting plans to advance into a Phase 2b study combining the drug with chemotherapy. In heavily pretreated third-line patients, median overall survival exceeded five months, with durable disease control and several long-survivor signals supporting continued development.
Can-Fite BioPharma is set to raise approximately $4 million through the immediate exercise of existing warrants, significantly impacting its funding for research and development activities. The new warrants to be issued will further strengthen the company’s capital position, expected to close by March 5, 2026.
